ClearPoint Neuro, Inc. (reported as MRI Interventions, Inc.) — Q1 2015 Form 10-Q
Business context and reporting period. This unaudited quarterly report covers the three months ended March 31, 2015. The filing identifies the registrant as MRI Interventions, Inc. Its commercial ClearPoint system supports MRI-guided minimally invasive brain procedures; ClearTrace, intended for heart procedures, remained under development and was not cleared for commercial sale.
Financial results and position
| Metric | Q1 2015 | Q1 2014 / prior balance |
|---|---|---|
| Total revenue | $1.010 million | $0.823 million |
| Net income (loss) | $(3.945) million | $2.630 million |
| Operating cash flow | $(2.799) million | $(1.359) million |
| Cash and cash equivalents | $6.438 million at March 31 | $9.244 million at December 31, 2014 |
| Total assets | $10.745 million | $13.386 million at December 31, 2014 |
| Total liabilities | $14.375 million | $13.486 million at December 31, 2014 |
| Stockholders’ deficit | $(3.630) million | $(0.100) million at December 31, 2014 |
- Product revenue was $976,871; other service revenue was $33,532. No development-service revenue was recorded, versus $98,862 in Q1 2014.
- Management reported gross margin on product revenues of 60%, compared with 51% in Q1 2014, citing higher production volumes and favorable product mix.
- Current assets were $9.177 million and current liabilities $5.625 million at quarter-end. The filing reports $11.014 million of scheduled note principal payments, including $4.289 million due in 2016 and $3.725 million in 2019; carrying values are reduced by debt discounts.
- Cash declined by $2.806 million during the quarter. Investing cash use was $6,635; there were no financing cash flows in Q1 2015.
Material changes versus the prior comparable period
- Revenue increased 23% overall. Product and other service revenue rose 40%, including a 49% increase in disposable-product sales to $840,000, while development-service revenue ended with completion of a contract project.
- Operating expenses included $753,400 of restructuring charges, versus none in Q1 2014. Research and development costs fell 35% to $527,512; selling, general and administrative expenses rose 27% to $2.289 million.
- Q1 2014 included a $4.339 million gain from selling certain intellectual property to Boston Scientific in exchange for cancellation of related-party notes. This nonrecurring gain materially affects the comparison of reported earnings.
- Q1 2015 included a $782,802 loss from remeasurement of warrant derivative liabilities, versus a $483,790 gain in Q1 2014. Interest expense increased to $307,813 from $151,408.
Outlook, commentary and risks
- Management expected cash on hand at March 31, combined with expected product-sale cash generation, to fund anticipated requirements through at least March 31, 2016. It also expected ClearPoint revenue to grow during 2015 through increased utilization at existing sites and more installed sites. These are management expectations, not assurances.
- The company expected continued operating losses and cash use. It said further financing may be needed if available resources prove insufficient; additional equity or convertible-debt financing could dilute shareholders, and financing may not be available on acceptable terms.
- The company announced consolidation of major functions at its Irvine headquarters and planned to close its Memphis office in May 2015. Seven employees, including three executives, were affected; approximately $718,000 of the restructuring charge related to severance and compensation, with most expected to be paid in Q2 2015. The full-time executive chairman position was eliminated in April.
- Key risks include limited market adoption and customer concentration for ClearPoint, reimbursement uncertainty, reliance on suppliers and limited manufacturing capacity, regulatory and development uncertainty for ClearTrace, competition, and dependence on additional capital. Three customers represented 50% of accounts receivable at March 31; two customers generated 31% of Q1 product revenue.
- Warrant derivative liabilities were $2.981 million and measured using Level 3 inputs, making reported earnings sensitive to valuation assumptions. The filing reported no legal proceedings, no material off-balance-sheet arrangements, and effective disclosure controls as of March 31, 2015.
Important facts for investors to verify
- Confirm the registrant’s identity and relationship, if any, to ClearPoint Neuro, Inc.; this filing names MRI Interventions, Inc.
- Track cash burn against management’s stated runway through March 31, 2016, and verify whether subsequent financing or spending changes affect that estimate.
- Assess whether ClearPoint disposable-product growth and installed-site utilization continue, and whether customer concentration changes.
- Review debt maturities, interest obligations, warrant terms and fair-value assumptions, including the 2016 Brainlab note maturity.
- Verify restructuring cash costs and execution of the Memphis-to-Irvine consolidation, and monitor ClearTrace development and regulatory progress.